TARGET investigators are analyzing tumors from pediatric patients to identify biomarkers that correlate with poor clinical outcome and/or new therapeutic approaches to treat childhood Osteosarcoma (OS). The tissues used in this study were collected from patients enrolled in Children's Oncology Group (COG) biology studies and clinical trials and through a collaboration with The Hospital for Sick Children (SickKids) in Toronto, Ontario, Canada.
The OS project team members (like other TARGET researchers) are generating data in two phases: Discovery and Validation. Visit the TARGET Research page to learn more.
The TARGET osteosarcoma (OS) project has produced comprehensive genomic profiles of nearly 100 clinically annotated patient cases within the discovery dataset. Each fully-characterized TARGET OS case includes data from nucleic acid samples extracted from tumor and normal tissues as follows:
- Primary tumor sample collected at the time of diagnostic surgery
- Normal tissue sample from peripheral blood (case-matched)
Additional cases with partial molecular characterization and/or sequencing data are available to the research community.
Case Selection Criteria
Tissues and clinical data used for the TARGET OS project were obtained from patients enrolled on biology studies and clinical trials managed through the Children’s Oncology Group (COG) and through a collaboration with the Hospital for Sick Children (SickKids) in Toronto (Ontario, Canada). Patient samples with full characterization were chosen based on the following criteria:
- Tumor cellularity of >50% in tumor specimens and tumor necrosis of <50%
- High-quality nucleic acids in amounts adequate to complete comprehensive genomic profiling
The TARGET OS project team relied on a variety of platforms to obtain a fully characterized dataset of nearly 100 cases. The COG OS Statistics and Data Center and personnel from Toronto SickKids provided clinical annotations and outcome data for all cases. Visit the TARGET Project Experimental Methods page for detailed information and protocols.
||COG & SickKids Protocols
||Affymetrix U133 Plus 2.0 Array
|Chomosome Copy Number Analyses & Loss of Heterozygosity
||Affymetrix SNP 6.0 Array
|Epigenetics (DNA Methylation)
||Illumina Infinium 450K
||MegaPlex TaqMan Array
|Whole Genome Sequencing
||Complete Genomics Incorporated,
Illumina Hi-Seq 2000
|Whole Exome Sequencing
||Illumina Genome Analyzer II or Hi-Seq 2000
||Illumina Genome Analyzer IIx, Hi-Seq 2000 or Mi-Seq
Verification of Discovery Variants
The TARGET OS project team utilized a variety of sequencing approaches to confirm candidate variants identified in the discovery sample cohort as somatic. For example, mRNA-seq results are being used to determine variants which were expressed and originally identified through whole genome or exome sequencing. These verified variants will be made available as open-access data.
Some sequence mutations identified in the discovery cohort, along with some previously published variants, are being further analyzed in an additional 200 or so cases. This validation effort is being performed in an unbiased cohort that was randomly selected based on tissue availability from patients enrolled on COG protocols and/or studies run through additional collaborative efforts, which allows for determination of the frequency of these changes across a broader spectrum of OS subtypes.
All data from the discovery and validation efforts are made available as specified in the Using TARGET Data and TARGET Publication Guidelines pages. The TARGET Data Matrix provides an overview of the data generated and described above.